Follicum initiates collaboration with Bioglan for the production of FOL-005 cream for upcoming clinical trial on patients with hair loss
Lund, Sweden, September 26. Follicum today announces the signing of a cooperation agreement with Bioglan AB for the production of clinical trial material of Follicum's new, cream-like formulation of FOL-005 for topical treatment. The formulation will be used in the Phase II clinical trial on hair loss, which is expected to start in the beginning of 2020.In mid-June this year, Follicum announced that the company had conducted a successful, scientific advisory meeting with the German Medicines Agency, BfArM, concerning the upcoming clinical trial with FOL-005. As previously communicated, the